In situ mineralization of 3D printed metastable calcium species
A biomimetic 3D printing ink with metastable calcium compounds and oligopeptides enables hardening of calcium-based articles like bone and nacre without sintering, ensuring structural integrity and efficiency in 3D printing.
Patent Information
- Application Number
- JP2024532954
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-02
- Filing Date
- 2022-11-28
- Publication Date
- 2024-11-15
AI Technical Summary
Existing 3D printed calcium-based articles, such as bone, teeth, and nacre mimics, require sintering for sufficient hardness and crystallization, which is inefficient and may alter their structural integrity.
A biomimetic mineralizable 3D printing ink comprising metastable calcium carbonate or phosphate, a carrier material, and a crystallization trigger substance, such as oligopeptides, allows for hardening without sintering by controlled crystallization.
The ink achieves sufficient hardness and structural integrity in 3D printed articles like bone, teeth, and nacre substitutes through controlled crystallization at ambient conditions, maintaining the desired properties without sintering.
Smart Images

Figure 2024542773000007 
Figure 2024542773000008 
Figure 2024542773000009
Abstract
Description
[Technical field]
[0001] The present invention relates to biomimetic mineralizable 3D printing inks, methods for producing such biomimetic mineralizable 3D printing inks, methods for producing biomineralized 3D printed articles, biomineralized 3D printed articles, and also the use of a crystallization trigger, which is an oligopeptide selected from the group comprising oligopeptides of the HABP family and oligopeptides of the P11 family, for 3D printing. [Background technology]
[0002] 3D (three-dimensional) printing is typically performed under computer control such that materials such as plastics or liquids are deposited, bonded, or solidified to produce three-dimensional objects, which are typically built up layer by layer. In view of the fact that this technique can be used to build a wide variety of objects for specific purposes, 3D printing can be used in a variety of application fields. Also in the field of biomaterials and tissue engineering, this technique is of great interest for the purpose-built production of dental reconstruction materials, ceramic substitutes, mollusc shell substitutes, nacre substitutes, dentin substitutes, tooth substitutes, or bone substitutes.
[0003] For example, CN108126244(A) relates to a biomineralized 3D printing ink characterized by comprising a hydrogel, the hydrogel comprising concentrated sodium alginate and sodium alginate complex containing a phosphorus source, the concentration range of the phosphorus source being 0.1mol / L-1.5mol / L, the mass fraction of sodium alginate in the hydrogel being 10%-20%, and the mass fraction of alginate complex in the hydrogel being 5%-20%.CN106668934(B) relates to a method for producing a biomedical calcium phosphate-based 3D printing material, comprising immersing amorphous calcium phosphate in pure water containing metal ions, rare earth ions, and a water-soluble polymer, followed by drying and grinding to obtain a calcium phosphate-based 3D printing material, the water-soluble polymer being at least one of polyvinyl alcohol, sodium carboxymethylcellulose, hydroxyethylcellulose, polyvinylpyrrolidone, and starch. CN109999223(A) relates to an adjustable artificial bone repair system for repairing alveolar bone, characterized by the following components: 1 degradable natural polymer, 2 degradable artificial polymer, 3 bioceramic, 4 metal. CN108295306(A) relates to a 3D printing hydrogel material with mesoporous nano calcium phosphate particle filler, including calcium phosphate particles and hydrogel material, the calcium phosphate particles are uniformly dispersed in the hydrogel material, the calcium phosphate particle surface is modified with polyethylene glycol, the calcium phosphate particles are hollow spheres or ellipsoids with a crystalline shell, and the pore size of the calcium phosphate particles is mainly 20nm-70nm.US Patent Application Publication No. 2018243980(A1) relates to a system for three-dimensional printing and mineralizing polymers, the system comprising a three-dimensional printer unit having a syringe extruder, a fluid supply system operably coupled to the three-dimensional printer unit, and a control unit operably coupled to the three-dimensional printer unit and the fluid supply system, the control unit configured to cause the three-dimensional printer unit to print a portion of a three-dimensional polymer object, cause the fluid supply system to wash the portion of the three-dimensional polymer object with a fluid to mineralize the portion of the three-dimensional polymer object, and cause the three-dimensional printer unit to print a next portion of the three-dimensional polymer object.
[0004] Chinese Patent No. 104147641(B) relates to a bone repair material for personalization, comprising an organic material and an inorganic material in a mass ratio of 0.1-0.6:1, and a lipid microsphere powder coated with protein, wherein the organic material is selected from the group consisting of PLGA, PLA, and PGA, and PLA:PGA=5%-95%:95%-5%, the molecular weight range is 8000-250000, the PLA molecular weight is in the range of 8000-250000, and the PGA molecular weight range is 8000-250000, the inorganic material is a calcium phosphate salt selected from one or more of β-tricalcium phosphate, α-tricalcium phosphate, hydroxyapatite, and tetracalcium phosphate, the protein encapsulated in the lipid microsphere is recombinant human interferon β, and the content of recombinant human interferon β in each lipid microsphere powder is 50-200ng / dose. Korean Patent Publication No. 20180128227(A) relates to a filament composite resin composition for FDM-3D printing, comprising a biocompatible polymer, a bone-activating ceramic, and a dispersant, the bone-activating ceramic having a particle size of 100 nm to 800 nm. Chinese Patent Publication No. 108815574(A) relates to a bone-repairing hydrogel stent, characterized in that the bone-repairing hydrogel stent comprises a polymer gel carrier and mineralized nano-bone particles, the polymer gel carrier comprising a polymer gel and a matrix metalloproteinase. In response to the peptide chain, the polymer gel is directly cross-linked with the matrix metalloproteinase-responsive peptide chain, and the bone-repairing hydrogel scaffold is subjected to 3D printing under ultraviolet excitation.
[0005] However, prior art 3D printed articles suffer from several drawbacks, in particular, calcium-based 3D printed articles that may be used to mimic bone, teeth, shells, and / or nacre typically need to be sintered to achieve sufficient hardness and crystallization.
[0006] Thus, while it is possible to produce 3D printed objects, such as calcium-based 3D printed objects that can be used to mimic bone, teeth, shells, and / or nacre, these objects typically need to be sintered to achieve sufficient hardness and crystallization. Summary of the Invention [Problem to be solved by the invention]
[0007] It is therefore an object of the present invention to provide a 3D printing ink suitable for the production of biomineralized 3D printed articles based on calcium materials. A further object of the present invention is that the biomineralized 3D printed articles are suitable for mimicking bone, teeth, shells and / or nacre. Another object of the present invention is that the biomimetic mineralized 3D printed articles provide sufficient hardness and can achieve hardening without sintering.
[0008] One or more of the above objects and other objects are solved by the subject matter defined herein in the independent claims. Advantageous embodiments of the invention are defined in the corresponding dependent claims. [Means for solving the problem]
[0009] The present invention therefore relates to a biomimetic mineralizable 3D printing ink comprising: (a) a calcium cation-based compound which is a metastable calcium carbonate or a metastable calcium phosphate; (b) a carrier material, and (c) Crystallization trigger material.
[0010] According to one embodiment, the calcium cation based compound has a crystallinity of less than 50% by weight, preferably less than 40% by weight, more preferably less than 30% by weight, and most preferably less than 20% by weight, based on the total weight of the calcium cation based compound.
[0011] According to another embodiment, the calcium cation-based compound has a weight median particle size d, determined by dynamic light scattering, in the range of 1 to 500 nm, preferably 50 to 400 nm, and most preferably 100 to 350 nm. 50 has.
[0012] According to yet another embodiment, the carrier material is a material suitable for forming a hydrogel, preferably the carrier material is selected from the group including gelatin, methylcellulose, alginate, agarose, fibrin, hyaluronic acid, proteins such as gelatin, nidogen, collagen, and heparan sulfate proteoglycans, and mixtures thereof, K-carrageenan, poly(ethylene glycol) (PEG), polycaprolactone (PCL), poloxamer, peptides, and mixtures thereof.
[0013] According to one embodiment, the crystallization trigger substance is a peptide, oligopeptide, or protein, preferably, the crystallization trigger substance is an oligopeptide, more preferably, the crystallization trigger substance is an oligopeptide comprising 11 amino acid residues and comprising a hydrophobic aromatic core.
[0014] According to another embodiment, the crystallization trigger substance is an oligopeptide of the HABP family, preferably HABP1 and HABP2, and an oligopeptide of the P11-family, preferably P11-4, P11-8, P11-9, P11-12, P11-13, P11-14, P11-15, P11-16, P11-17, P11-18, P11-19, P11-20, P11-24, P11-25, P11-26, P11-27, P11-28- P11-29, P11-30, P11-31, P11-32, and mixtures, most preferably selected from the group including P11-4, optionally in association with a negatively charged polysaccharide or a positively charged polysaccharide.
[0015] According to yet another embodiment, the crystallization trigger substance is an oligopeptide in which the amino acids at positions 4 and 8 are phenylalanine (F) and the amino acid at position 6 is tryptophan (W), and / or both amino acid residues at positions 5 and 7 of the peptide are ornithine (O) or glutamic acid (E).
[0016] According to one embodiment, the ink comprises: (a) a calcium cation-based compound in an amount ranging from 2 to 30% by weight, preferably from 5 to 25% by weight, and most preferably from 10 to 25% by weight, based on the total weight of the ink; and (b) a carrier material in an amount ranging from 1 to 10% by weight, preferably from 1 to 8% by weight, and most preferably from 1 to 5% by weight, based on the total weight of the ink; and (c) a crystallization trigger substance in an amount ranging from 0.05 to 3% by weight, preferably from 0.05 to 2.8% by weight, and most preferably from 0.1 to 2.5% by weight, based on the total weight of the ink; and (d) a buffer in an amount ranging from 57 to 96.95% by weight, preferably from 64.2 to 93.95% by weight, and most preferably from 67.5 to 98.9% by weight, based on the total weight of the ink; Includes.
[0017] According to one embodiment, the calcium cation based compound, which is a metastable calcium carbonate or a metastable calcium phosphate, comprises a stabilizing agent.
[0018] According to another embodiment, the stabilizer is selected from the group comprising magnesium chloride, polyaspartic acid, glutamic acid, polyacrylic acid, phosphates such as LO-phosphoserine, sodium dihydrogen phosphate, and disodium hydrogen phosphate, sugars, EDTMP, xanthan, polysorbates, citric acid, ethylenediamine, extracts from biological samples, double hydrophilic block copolymers, and mixtures thereof.
[0019] According to a further aspect there is provided a method of manufacturing a biomimetic mineralizable 3D printing ink as defined herein, the method comprising: (a) providing a calcium cation-based compound which is a metastable calcium carbonate or a metastable calcium phosphate; (b) providing a carrier material; (c) providing a crystallization trigger substance; and (d) mixing the calcium cation-based compound, which is a metastable calcium carbonate or a metastable calcium phosphate of step (a), the carrier material of step (b), and the crystallization trigger substance of step (c); Includes.
[0020] According to another aspect, there is provided a method for producing a biomineralized 3D printed article, the method comprising: (a) providing a biomimetic mineralizable 3D printing ink as defined herein; (b) printing the biomimetic mineralizable 3D printing ink into a predetermined shape using a 3D printer; and (c) curing the biomimetic mineralizable 3D printing ink at a temperature in the range of 10-50°C, preferably 15-45°C, to obtain a biomineralized 3D printed article; Includes.
[0021] According to one embodiment, the curing in step (c) comprises: (a) at a temperature in the range of 15 to 40°C, most preferably in the range of 20 to 40°C, and / or (b) a curing time ranging from 2 hours to 21 days, preferably from 12 hours to 19 days, and most preferably from 24 hours to 18 days; and / or (c) CO in an atmosphere of 3 to 6% by volume, preferably 4 to 6% by volume, and most preferably 4.5 to 5.5% by volume. 2 In content, and / or (d) at a humidity of greater than 75% by volume, preferably in the range of 80 to 100% by volume, and most preferably in the range of 85 to 99.5% by volume; It will be held.
[0022] According to another embodiment, the method further comprises a step (d) of drying the biomineralized 3D printed article obtained in step (c), preferably at a temperature of at least 50°C, more preferably at a temperature in the range of 60-100°C, most preferably 65-90°C, and / or for a drying time in the range of 5 hours to 36 hours, preferably 5 hours to 32 hours, most preferably 6 hours to 26 hours.
[0023] According to another aspect, there is provided a biomineralized 3D printed article obtainable by the method defined herein.
[0024] According to one embodiment, the article is a dental reconstruction material, a ceramic substitute, a mollusk shell substitute, a mother of pearl substitute, a dentin substitute, a tooth substitute, or a bone substitute.
[0025] According to a further aspect, there is provided the use of a crystallization trigger substance, which is an oligopeptide selected from the group comprising the HABP family of oligopeptides and the P11 family of oligopeptides, for 3D printing.
[0026] For purposes of the present invention, the following terms shall be understood to have the following meanings.
[0027] Where the term "comprising" is used in the present specification and claims, it does not exclude other elements. For the purposes of the present invention, the term "consisting of" is considered to be a preferred embodiment of the term "comprising of". Hereinafter, when a group is defined as comprising at least a certain number of embodiments, this is also to be understood as disclosing a group that preferably consists only of these embodiments.
[0028] Where an indefinite or definite article is used when referring to a singular noun such as "a", "an" or "the", this also includes the plural of that noun, unless otherwise stated.
[0029] Terms such as "can be obtained" or "can be defined" and "obtained" or "defined" are used interchangeably. What this means, for example, is that unless the context clearly indicates otherwise, the term "obtained" is not meant to indicate that an embodiment must be obtained by, for example, the sequence of steps following the term "obtained", but such a limited understanding is always included as a preferred embodiment by the term "obtained" or "defined".
[0030] According to the present invention, a biomimetic mineralizable 3D printing ink comprises: (a) a calcium cation-based compound which is a metastable calcium carbonate or a metastable calcium phosphate; (b) a carrier material, and (c) a crystallization trigger substance; Includes.
[0031] It has in particular been found that a biomimetic mineralizable 3D printing ink according to the present invention must comprise a calcium cation based compound which is a metastable calcium carbonate or a metastable calcium phosphate, a carrier material, and a crystallization trigger substance.
[0032] In the following, reference is made to further details of the present invention, and in particular the biomimetic mineralizable 3D printing inks described above.
[0033] One requirement of the present invention is that the biomimetic mineralizable 3D printing ink comprises a calcium cation-based compound that is a metastable calcium carbonate or a metastable calcium phosphate.
[0034] The term "metastable" calcium carbonate is understood to mean calcium carbonate that has a low content of crystalline morphology or no crystalline morphology when analyzed by known means of determining the morphological state of the material. For example, metastable calcium carbonate has a crystallinity of less than 50% by weight, preferably less than 40% by weight, more preferably less than 30% by weight, and most preferably less than 20% by weight, based on the total weight of the calcium carbonate. Thus, metastable calcium carbonate is preferably amorphous calcium carbonate.
[0035] In addition, a "metastable" calcium carbonate therefore has a high content of amorphous form when analyzed by known means of determining the morphological state of a material, for example, a metastable calcium carbonate has more than 50% by weight, preferably more than 60% by weight, more preferably more than 70% by weight, and most preferably more than 80% by weight of amorphous phase, based on the total weight of the calcium carbonate.
[0036] Alternatively, the term "metastable" calcium carbonate refers to calcium carbonate that has a high content or consists of crystalline forms, which, when analyzed by known means of examining the morphological state of the material, are not stable and therefore transform into more stable calcium carbonate species. For example, metastable calcium carbonate has a crystallinity of more than 50% by weight, preferably more than 70% by weight, more preferably more than 80% by weight, most preferably more than 90% by weight, for example about 100% by weight, based on the total weight of the calcium carbonate. Thus, the metastable calcium carbonate is preferably vaterite, for example vaterite transformed into calcite.
[0037] Similarly, the term "metastable" calcium phosphate refers to calcium phosphate that has a low content of crystalline morphology or no crystalline morphology when analyzed by known means of determining the morphological state of the material. For example, metastable calcium phosphate has a crystallinity of less than 50% by weight, preferably less than 40% by weight, more preferably less than 30% by weight, and most preferably less than 20% by weight, based on the total weight of the calcium phosphate. Thus, metastable calcium phosphate is preferably amorphous calcium phosphate.
[0038] In addition, a "metastable" calcium phosphate therefore has a high content of amorphous form when analyzed by known means of determining the morphological state of the material, for example, a metastable calcium phosphate has more than 50% by weight, preferably more than 60% by weight, more preferably more than 70% by weight, and most preferably more than 80% by weight of amorphous phase, based on the total weight of the calcium phosphate.
[0039] Generally, the calcium cation-based compound therefore has a crystallinity of less than 50% by weight, preferably less than 40% by weight, more preferably less than 30% by weight, and most preferably less than 20% by weight, based on the total weight of the calcium cation-based compound.
[0040] In addition, the calcium cation-based compound therefore has a high content of amorphous form when analyzed by known means of determining the morphological state of a material, for example the calcium cation-based compound has more than 50% by weight, preferably more than 60% by weight, more preferably more than 70% by weight, most preferably more than 80% by weight of amorphous phase, based on the total weight of the calcium cation-based compound.
[0041] In order to maintain a high content of amorphous phase, it is preferred that the calcium cation-based compound has a low water content. According to one embodiment of the invention, the calcium cation-based compound has a water content of ≦10.0 wt.%, preferably 0.01-10.0 wt.%, more preferably 0.02-9.0 wt.%, most preferably 0.05-8.0 wt.%, based on the total dry weight of the calcium cation-based compound.
[0042] For example, the calcium cation-based compound is a metastable calcium carbonate having a water content of ≦10.0 wt.%, preferably 0.01-10.0 wt.%, more preferably 0.02-9.0 wt.%, and most preferably 0.05-8.0 wt.%, based on the total dry weight of the metastable calcium carbonate. In one embodiment, the calcium cation-based compound is an amorphous calcium carbonate having a water content of ≦10.0 wt.%, preferably 0.01-10.0 wt.%, more preferably 0.02-9.0 wt.%, and most preferably 0.05-8.0 wt.%, based on the total dry weight of the metastable calcium carbonate. In another embodiment, the calcium cation-based compound is vaterite having a water content of ≦10.0 wt.%, preferably 0.01-10.0 wt.%, more preferably 0.02-9.0 wt.%, and most preferably 0.05-8.0 wt.%, based on the total dry weight of the metastable calcium carbonate.
[0043] Alternatively, the calcium cation-based compound is a metastable calcium phosphate having a water content of ≦10.0 wt.%, preferably 0.01-10.0 wt.%, more preferably 0.02-9.0 wt.%, and most preferably 0.05-8.0 wt.%, based on the total dry weight of the metastable calcium phosphate. In one embodiment, the calcium cation-based compound is an amorphous calcium phosphate having a water content of ≦10.0 wt.%, preferably 0.01-10.0 wt.%, more preferably 0.02-9.0 wt.%, and most preferably 0.05-8.0 wt.%, based on the total dry weight of the metastable calcium phosphate.
[0044] It is preferred that the calcium cation-based compound has a particularly small particle size, preferably in the nanometer range, and the particle size of the calcium cation-based compound is controlled, in particular because it has a beneficial effect on the formation of crystals and on the curing, which can be accelerated by generating heat in the appropriate range in the ink.
[0045] In one embodiment, the calcium cation-based compound therefore preferably has a weight median particle size d in the range of 1 to 500 nm. 50 For example, the calcium cation-based compound has a weight median particle size d in the range of 50 to 400 nm, most preferably 100 to 350 nm. 50 has.
[0046] In one embodiment, the calcium cation-based compound has a weight median particle size d in the range of 1 to 500 nm, preferably 50 to 400 nm, and most preferably 100 to 350 nm. 50 It is a metastable calcium carbonate having the following structure:
[0047] In an alternative embodiment, the calcium cation-based compound has a weight median particle size d in the range of 1 to 500 nm, preferably 50 to 400 nm, and most preferably 100 to 350 nm. 50 It is a metastable calcium phosphate having the following structure:
[0048] Value d x Whereas x% of the particles are d x This means that the diameter is smaller than d 50 The value means that the particle size is smaller than this value for 50% of all particles. x Values are given in weight percent unless otherwise indicated. 50 The value is therefore the weight median particle size, ie the particle size below which 50% by weight of all particles are smaller.
[0049] Furthermore, the weight median particle size d 50It should be noted that refers to the primary particle size. That is, the calcium cation-based compound, which is a metastable calcium carbonate or a metastable calcium phosphate, is deagglomerated, preferably by grinding. Methods for deagglomerating solid agglomerated materials, such as calcium cation-based compounds, are known in the art, and each method known for this purpose may be used in the present invention. Preferably, such deagglomeration is carried out by using a grinding method, followed, if desired, by sieving to remove larger particles.
[0050] Additionally or alternatively, the calcium cation-based compound, which is a metastable calcium carbonate or a metastable calcium phosphate, has a BET specific surface area, measured using nitrogen and the BET method according to ISO 9277, of less than 1.0 m 2 / g~100.0m 2 / g, more preferably 5.0m 2 / g~80.0m 2 / g, most preferably 10.0m 2 / g~70.0m 2 For example, the BET specific surface area of a calcium cation-based compound, which is a metastable calcium carbonate, measured using nitrogen and the BET method according to ISO 9277, is in the range of 10.0 m 2 / g~70.0m 2 / g, more preferably 10.0m 2 / g~50.0m 2 / g, most preferably 15.0m 2 / g~40.0m 2 For example, the BET specific surface area of a calcium cation-based compound, which is a metastable calcium phosphate, measured using nitrogen and the BET method according to ISO 9277, is in the range of 10.0 m 2 / g~70.0m 2 / g, more preferably 25.0m 2 / g~70.0m 2 / g, most preferably 50.0m 2 / g~70.0m 2 / g.
[0051] It is understood that the metastable calcium carbonate or metastable calcium phosphate calcium cation-based compound may be obtained by any method known in the art. Preferably, the metastable calcium carbonate or metastable calcium phosphate calcium cation-based compound is obtained by a method comprising precipitation of the metastable calcium carbonate or metastable calcium phosphate calcium cation-based compound in an aqueous solution. For example, the precipitation may be carried out at a temperature in the range of 4-15°C, more preferably at a temperature in the range of 6-10°C. Additionally or alternatively, it is preferred that the precipitation is carried out at a pH of 7 or higher, more preferably at a pH in the range of 7-10. Additionally or alternatively, it is preferred that the concentration of the compound used for precipitation may vary from 0.02mM to 2M, preferably from 0.2mM to 1M.
[0052] It is understood that the precipitation is carried out as rapidly as possible so that the compounds used in the precipitation are preferably brought into contact with each other in one step.
[0053] In one embodiment, a calcium cation based compound that is a metastable calcium carbonate or a metastable calcium phosphate is obtained by the method described in the examples herein.
[0054] For example, when the calcium cation-based compound is a metastable calcium phosphate, the metastable calcium phosphate can be obtained by precipitating a calcium phosphate salt in an aqueous solution. The precipitation can be carried out by contacting an aqueous solution of diammonium phosphate with an aqueous solution of calcium nitrate tetrahydrate in one step. In a further step, the precipitated metastable calcium phosphate can be separated from the liquid phase, for example by filtration. The obtained metastable calcium phosphate can be subjected to a further step of washing, for example by freeze-drying.
[0055] For example, when the calcium cation-based compound is metastable calcium carbonate, the metastable calcium carbonate can be obtained by precipitating calcium carbonate salt in an aqueous solution. The precipitation can be carried out by contacting an aqueous sodium carbonate solution with an aqueous calcium chloride solution in one step. In a further step, the precipitated metastable calcium carbonate can be separated from the liquid phase, for example by filtration. The obtained metastable calcium carbonate can be subjected to a further step of washing, for example by freeze-drying.
[0056] The biomimetic mineralizable 3D printing ink is further required to include a carrier material. It is particularly noted that the carrier material provides a matrix in which the calcium cation-based compound and the crystallization trigger substance are dispersed. A further benefit of the carrier is that the calcium cation-based compound and the crystallization trigger substance are intertwined so that the solids of the slurry do not separate from the liquid during extrusion. In addition to this, the carrier provides structural support to the 3D printing structure and also provides the possibility to adjust the viscosity of the ink.
[0057] In particular, as the carrier material in the biomimetic mineralizable 3D printing ink of the present invention, any carrier material typically used in the type of material to be produced may be used. Since the article to be produced is in particular used as a dental reconstruction material, a ceramic substitute, a mollusc shell substitute, a nacre substitute, a dentin substitute, a tooth substitute or a bone substitute, it is particularly preferred that the carrier material is biocompatible, has very good hydrophilicity, is non-biotoxinous and non-immunogenic. For example, the carrier material is approved by the FDA for use as a human body additive.
[0058] In one embodiment, the carrier material is suitable for forming hydrogel.Therefore, the carrier material is preferably a material that is three-dimensionally crosslinked and does not disintegrate in water.Furthermore, the carrier material affects the increase in viscosity but the decrease in flowability.In addition, the carrier material is preferably pH buffered.
[0059] For example, the carrier material is selected from the group including gelatin, methylcellulose, alginate, agarose, fibrin, hyaluronic acid, proteins such as gelatin, nidogen, collagen, and heparan sulfate proteoglycan, and mixtures thereof, K-carrageenan, poly(ethylene glycol) (PEG), polycaprolactone (PCL), poloxamer, peptides, and mixtures thereof.
[0060] It is therefore understood that the carrier material is preferably a material suitable for forming a hydrogel and is selected from the group including gelatin, methylcellulose, alginate, agarose, fibrin, hyaluronic acid, proteins such as gelatin, nidogen, collagen, and heparan sulfate proteoglycans, and mixtures thereof, K-carrageenan, poly(ethylene glycol) (PEG), polycaprolactone (PCL), poloxamer, peptides, and mixtures thereof.
[0061] It is understood that the carrier material may be a mixture of the above-mentioned materials. For example, the carrier material may be a mixture of proteins. For example, the carrier material may be a mixture of proteins such as gelatin, nidogen, collagen, and heparan sulfate proteoglycan. Such carrier materials are known in the art and are available, for example, under the trade name Matrigel™.
[0062] In view of the above, the carrier material may be a naturally occurring or synthetically based hydrogel.
[0063] More precisely, when the carrier material is a hydrogel of natural origin, it is preferably selected from the group comprising, more preferably consisting of, gelatin, methylcellulose, alginate, agarose, fibrin, hyaluronic acid, proteins such as gelatin, nidogen, collagen and heparan sulfate proteoglycans, and mixtures thereof, K-carrageenan, and mixtures thereof.
[0064] Alternatively, when the carrier material is a naturally occurring hydrogel, it is preferably selected from the group comprising, more preferably consisting of, poly(ethylene glycol) (PEG), polycaprolactone (PCL), poloxamer, peptides, and mixtures thereof.
[0065] Since the article to be produced is used in particular as a dental reconstruction material, a ceramic substitute, a mollusc shell substitute, a nacre substitute, a dentin substitute, a tooth substitute or a bone substitute, it is preferred that the carrier material is a hydrogel of natural origin.
[0066] Most preferably, the carrier material is methylcellulose.
[0067] The biomimetic mineralizable 3D printing ink comprises a crystallization trigger material that is particularly advantageous as it controls the crystallization of a calcium cation based compound that is a metastable calcium carbonate or a metastable calcium phosphate such that controlled hardening of the biomimetic mineralizable 3D printing ink is obtained.
[0068] The crystallization trigger substance is preferably a peptide, an oligopeptide, or a protein. More preferably, the crystallization trigger substance is an oligopeptide. For example, the crystallization trigger substance is an oligopeptide of the HABP family, preferably an oligopeptide selected from the group including HABP1 and HABP2.
[0069] Most preferably, the crystallization trigger substance is an oligopeptide comprising 11 amino acid residues and comprising a hydrophobic aromatic core. In one embodiment, the crystallization trigger substance is an oligopeptide selected from the group comprising, and preferably consisting of, the HABP family of oligopeptides and the P11-family of oligopeptides. For example, the crystallization trigger substance is a P11-family of oligopeptide.
[0070] In one embodiment of the invention, oligopeptides comprising 11 amino acid residues and comprising a hydrophobic aromatic core have an overall net positive or negative charge, more preferably an even overall net charge, such as -6, -4, -2, +2, +4, or +6. Most preferably, oligopeptides comprising 11 amino acid residues and comprising a hydrophobic aromatic core have an overall net negative charge, more preferably an even overall net charge, such as -6, -4, or -2.
[0071] For example, the oligopeptides are P11-4 (sequence: CH3CO-QQRFEWEFEQQ-NH2), P11-8 (sequence: CH3CO-QQRFOWOFEQQ-NH2), P11-9 (sequence: CH3CO-SSRFEWEFESS-NH2), P11-12 (sequence: CH3CO-SSRFOWOFESS-NH2), P11-13 (sequence: CH3CO-EQEFEWEFEQE-NH2), P11-14 (Sequence: CH3CO-QQOFOWFOQQ-NH2), P11-15 (Sequence: CH3CO-NNRFEWEFENN-NH2), P11-16 (Sequence: CH3CO-NNRFOWOFENN-NH2), P11-17 (Sequence: CH3CO-TTRFEWEFETT-NH2), P11-18 (Sequence: CH3CO-TTRFOWOFETT-NH2), P11-19 (Sequence: CH3CO-QQRQOQO QEQQ-NH2), P11-20 (sequence: CH3CO-QQRQEQEQEQQ-NH2), P11-24 (sequence: CH3OH-SSRQEQEQESS-NH2), P11-25 (sequence: CH3CO-SSRSESESESS-NH2), P11-26 (sequence: CH3CO-QQOQOQOQQ-NH2), P11-27 (sequence: CH3CO-EQEQEQEQEQE-NH2), P11-28 (sequence: CHCO-OQOFOWOFOQO-NH2), P11-29 (sequence: CHCO-QQEFEWEFEQQ-NH2), P11-30 (sequence: CHCO-ESEFEWEFESE-NH2), P11-31 (sequence: CHCO-SSOFOWOFOSS-NH2), P11-32 (sequence: CHCO-OSOFOWOFOSO-NH2), and mixtures thereof.
[0072] In one embodiment, oligopeptides of the P11-family are positively charged, having an overall net even charge, eg, +2, +4, or +6.
[0073] It is understood that the P11-family of positively charged oligopeptides share sequence homology.
[0074] Preferably, the amino acid residues at positions 5 and 7 are ornithine (O). Preferably, the amino acid residues at positions 1 and 2 are the same, while the amino acid residues at positions 10 and 11 are reversed.
[0075] Preferably, the amino acid residues at positions 1 and 2 are the same and are selected from the group including serine (SS), glutamine (QQ), threonine (TT), and asparagine (NN).
[0076] Preferably, the amino acid residues at positions 10 and 11 are the same and are selected from the group including serine (SS), glutamine (QQ), threonine (TT), and asparagine (NN).
[0077] In some embodiments, the amino acid residues at positions 1, 2, 10, and 11 are the same, in which case they are all either serine (SS), glutamine (QQ), threonine (TT), or asparagine (NN).
[0078] Preferably, the amino acid residue at position 3 is either ornithine (O) or arginine (R).
[0079] Preferably, the amino acid residue at position 4 is either phenylalanine (F) or glutamine (Q).
[0080] Preferably, the amino acid residue at position 6 is either tryptophan (W) or glutamine (Q).
[0081] Preferably, the amino acid residue at position 8 is either phenylalanine (F) or glutamine (Q).
[0082] Preferably, the amino acid residue at position 9 is either glutamic acid (E) or glutamine (Q).
[0083] In one embodiment, the positively charged oligopeptides are P11-8 (sequence: CH3CO-QQRFOWOFEQQ-NH2), P11-12 (sequence: CH3CO-SSRFOWOFESS-NH2), P11-14 (sequence: CH3CO-QQOFOWFOQQ-NH2), P11-15 (sequence: CH3CO-NNRFEWEFENN-NH2), P11-16 (sequence: CH3CO-NNRFOWOFENN-NH2), P11-18 (sequence: CH3CO- P11-19 (Sequence: CHCO-QQRQOQOQEQQ-NH2), P11-26 (Sequence: CHCO-QQOQOQOQQOQQ-NH2), P11-28 (Sequence: CHCO-OQOFOWOFOQO-NH2), P11-31 (Sequence: CHCO-SSOFOWOFOSS-NH2), P11-32 (Sequence: CHCO-OSOFOWOFOSO-NH2), and mixtures thereof.
[0084] Preferably, the positively charged oligopeptide is selected from the group consisting of P11-14 (sequence: CH3CO-QQOFOWFOQQ-NH2), P11-28 (sequence: CH3CO-OQOFOWOFOQO-NH2), P11-31 (sequence: CH3CO-SSOFOWOFOSS-NH2), and mixtures thereof.
[0085] It is understood that the amino acid chain of the oligopeptide may be extended to include a bioactive peptide sequence, or the amino acid chain is conjugated to a therapeutically active molecule or drug or the like.
[0086] In one embodiment, the P11-family oligopeptide is positively charged and is associated with a negatively charged polysaccharide.
[0087] Preferably, the polysaccharide is selected from the group comprising glycosaminoglycans, oligosaccharides, mucopolysaccharides, and dextran. Preferably, the oligopeptide of the P11-family is complexed with an oppositely charged polysaccharide, e.g. a negatively charged polysaccharide. In one embodiment, the negatively charged polysaccharide is a glycosaminoglycan (GAG) and is selected from the group comprising chondroitin sulfate (CS), dermatan sulfate, keratan sulfate, hyaluronan, hyaluronic acid, heparin, and heparan sulfate, or derivatives thereof. The polysaccharide may be natural or synthetic. The peptide complex may be selected from a SAP:polysaccharide combination, a SAP:oligosaccharide combination, and a SAP:GAG combination. In particular, the peptide complex is a SAP:GAG combination.
[0088] For example, oligopeptides of the P11-family are positively charged peptides that are associated with a polysaccharide selected from the group including glycosaminoglycans (GAGs), oligosaccharides, mucopolysaccharides, and dextran.
[0089] Throughout this application, a complex of an oligopeptide of the P11-family and a charged polysaccharide may be referred to as, for example, peptide:glycan or peptide:GAG or P11:glycan or P11:GAG.
[0090] In one embodiment, the oligopeptides are: P11-8 (sequence: CHCO-QQRFOWOFEQQ-NH2):GAG, P11-12 (sequence: CHCO-SSRFOWOFESS-NH2):GAG, P11-14 (sequence: CHCO-QQOFOWFOQQ-NH2):GAG, P11-15 (sequence: CHCO-NNRFEWEFENN-NH2):GAG, P11-16 (sequence: CHCO-NNRFOWOFENN-NH2):GAG, P11-18 (sequence: CHCO-TTRFO P11-19 (sequence: CH3CO-QQRQOQOQEQQ-NH2):GAG, P11-26 (sequence: CH3CO-QQOQOQOQOQQ-NH2):GAG, P11-28 (sequence: CH3CO-OQOFOWOFOQO-NH2):GAG, P11-31 (sequence: CH3CO-SSOFOWOFOSS-NH2):GAG, P11-32 (sequence: CH3CO-OSOFOWOFOSO-NH2):GAG, and mixtures thereof.
[0091] For example, the positively charged oligopeptide is selected from the group consisting of P11-14 (sequence: CH3CO-QQOFOWFOQQ-NH2):GAG, P11-28 (sequence: CH3CO-OQOFOWOFOQO-NH2):GAG, P11-31 (sequence: CH3CO-SSOFOWOFOSS-NH2):GAG, and mixtures thereof.
[0092] Alternatively, the P11-family of oligopeptides is negatively charged and has an even overall net charge, such as -2, -4, or -6. Preferably, the P11-family of negatively charged oligopeptides has an overall net negative charge of -2.
[0093] It is understood that the P11-family of negatively charged oligopeptides share sequence homology.
[0094] Preferably, the amino acid residues at positions 5, 7, and 9 are glutamic acid (E).
[0095] Preferably, the amino acid residue at position 3 is either glutamic acid (E) or arginine (R).
[0096] Preferably, the amino acid residues at positions 4 and 8 are the same and are preferably selected from the group consisting of phenylalanine (F), glutamine (Q), and serine (S). Preferably, the amino acid residue at position 6 is selected from the group consisting of tryptophan (W), glutamine (Q), and serine (S).
[0097] Preferably, the amino acid residues at positions 1 and 2 may be the same or different, and the amino acid residues at positions 10 and 11 are reversed.
[0098] Preferably, the amino acid residues at positions 1 and 2 are the same and are selected from the group including serine (SS), glutamine (QQ), threonine (TT), and asparagine (NN).
[0099] Preferably, the amino acid residues at positions 10 and 11 are the same and are selected from the group including serine (SS), glutamine (QQ), threonine (TT), and asparagine (NN).
[0100] In one embodiment, the crystallization trigger substance is an oligopeptide in which the amino acids at positions 4 and 8 are phenylalanine (F) and the amino acid at position 6 is tryptophan (W).
[0101] Additionally or alternatively, the crystallization trigger substance is an oligopeptide in which both amino acid residues at positions 5 and 7 of the peptide are ornithine (O) or glutamic acid (E).
[0102] For example, the crystallization trigger substance is an oligopeptide in which the amino acids at positions 4 and 8 are phenylalanine (F) and the amino acid at position 6 is tryptophan (W), or in which both amino acid residues at positions 5 and 7 of the peptide are ornithine (O) or glutamic acid (E).
[0103] Preferably, the crystallization trigger substance is an oligopeptide in which the amino acids at positions 4 and 8 are phenylalanine (F), the amino acid at position 6 is tryptophan (W), and both amino acid residues at positions 5 and 7 of the peptide are ornithine (O) or glutamic acid (E).
[0104] For example, the oligopeptides are P11-4 (sequence: CH3CO-QQRFEWEFEQQ-NH2), P11-9 (sequence: CH3CO-SSRFEWEFESS-NH2), P11-13 (sequence: CH3CO-EQEFEWEFEQE-NH2), P11-15 (sequence: CH3CO-NNRFEWEFENN-NH2), P11-17 (sequence: CH3CO-TTRFEWEFETT-NH2), P11-20 (sequence: CH3CO-QQRQEQ EQEQQ-NH2), P11-24 (sequence: CH3OH-SSRQEQEQESS-NH2), P11-25 (sequence: CH3CO-SSRSESESESS-NH2), P11-27 (sequence: CH3CO-EQEQEQEQEQE-NH2), P11-29 (sequence: CH3CO-QQEFEWEFEQQ-NH2), P11-30 (sequence: CH3CO-ESEFEWEFESE-NH2), and mixtures thereof.
[0105] Preferably, the oligopeptide is selected from the group consisting of P11-4 (sequence: CH3CO-QQRFEWEFEQQ-NH2), P11-13 (sequence: CH3CO-EQEFEWEFEQE-NH2), P11-29 (sequence: CH3CO-QQEFEWEFEQQ-NH2), P11-30 (sequence: CH3CO-ESEFEWEFESE-NH2), and mixtures thereof.
[0106] Most preferably, the P11-family oligopeptide is P11-4 (sequence: CH3CO-QQRFEWEFEQQ-NH2).
[0107] It will be appreciated that when negatively charged oligopeptides of the P11-family are used, it may be desirable to use positively charged polysaccharides such as chitosan and its derivatives or other cationic polysaccharides. Alternatively, when the complex comprises a positively charged oligopeptide of the P11-family, it may be desirable to use positively charged (i.e., of the same charge) polysaccharides such as chitosan and its derivatives or other cationic polysaccharides.
[0108] Preferably, the oligopeptide of the P11-family has an elastic modulus in the range of 1 to 400,000 Pa.
[0109] The ratio of P11-family oligopeptide to GAG in the complex is selected depending on the required mechanical properties and also on the required viscosity.
[0110] It will be appreciated that the biomimetic mineralizable 3D printing ink preferably has a viscosity in the range of 200-800 Pa·s, measured with a conventional Brookfield viscometer, for example type EV-2+, using disc spindle 3 and 100 rpm.
[0111] Preferably, the oligopeptide of the P11-family forms a gel or gel-like substance (hydrogel) within a few seconds up to 24 hours. It should be noted that the time for forming the gel or gel-like substance (hydrogel) depends on the buffer system used and can be selected according to the desired needs. When the oligopeptide of the P11-family is associated with a polysaccharide selected from the group including glycosaminoglycans (GAG), the oligopeptide preferably forms a gel or gel-like substance (hydrogel) before the oligopeptide and the GAG are mixed.
[0112] Also provided are charged oligopeptides of the P11-family, in which the amino acid chain has been extended to include a biologically active peptide sequence, or in which the amino acid chain has been linked to a therapeutically active molecule or drug or the like.
[0113] It should be noted that the crystallization trigger substance may also function as a carrier material. In this case, the crystallization trigger substance and the carrier material are the same. For example, when the crystallization trigger substance acts as a carrier material, i.e., the crystallization trigger substance and the carrier material are the same, the crystallization trigger substance and the carrier material are preferably collagen.
[0114] It is understood that the biomimetic mineralizable 3D printing ink may further comprise a buffer, preferably a buffer typically used in the type of material to be produced. A buffer is advantageously used to buffer the ink in a pH range around 7 to avoid dissolution of calcium cation-based compounds. Furthermore, a buffer is used to keep all possible charges in solution stable, including peptides, inorganic additives, and cells that may be present.
[0115] For example, the buffer may be selected from the group including PBS buffer, Tris buffer, citrate buffer, borate buffer, and the like.
[0116] In view of the above, biomimetic mineralizable 3D printing inks are (a) a calcium cation-based compound in an amount ranging from 2 to 30% by weight, based on the total weight of the ink; and (b) a carrier material in an amount ranging from 1 to 10% by weight, based on the total weight of the ink; and (c) a crystallization trigger substance in an amount ranging from 0.05 to 3% by weight, based on the total weight of the ink; and (d) a buffer in an amount ranging from 57 to 96.95% by weight, based on the total weight of the ink; Includes.
[0117] For example, biomimetic mineralizable 3D printing inks: (a) a calcium cation-based compound in an amount ranging from 5 to 25% by weight, most preferably from 10 to 25% by weight, based on the total weight of the ink; (b) a carrier material in an amount ranging from 1 to 8% by weight, most preferably from 1 to 5% by weight, based on the total weight of the ink; and (c) a crystallization trigger substance in an amount ranging from 0.05 to 2.8% by weight, most preferably 0.1 to 2.5% by weight, based on the total weight of the ink; and (d) a buffer in an amount ranging from 64.2 to 93.95% by weight, most preferably from 67.5 to 98.9% by weight, based on the total weight of the ink; Includes.
[0118] In order to stabilize the form of the calcium cation-based compound which is a metastable calcium carbonate or a metastable calcium phosphate, the calcium cation-based compound preferably contains a stabilizer.
[0119] Preferably, the stabilizer is selected from the group including magnesium chloride, polyaspartic acid, glutamic acid, polyacrylic acid, phosphates such as LO-phosphoserine, sodium dihydrogen phosphate, and disodium hydrogen phosphate, sugars, EDTMP, xanthan, polysorbates, citric acid, ethylenediamine, extracts from biological samples, double hydrophilic block copolymers, and mixtures thereof.
[0120] Thus, in one embodiment, the biomimetic mineralizable 3D printing ink comprises: (a) a calcium cation-based compound including a stabilizer in an amount ranging from 2 to 30% by weight based on the total weight of the ink; (b) a carrier material in an amount ranging from 1 to 10% by weight, based on the total weight of the ink; and (c) a crystallization trigger substance in an amount ranging from 0.05 to 3% by weight, based on the total weight of the ink; and (d) a buffer in an amount ranging from 57 to 96.95% by weight, based on the total weight of the ink; The composition comprises, and preferably consists of,
[0121] For example, biomimetic mineralizable 3D printing inks: (a) a calcium cation-based compound with a stabilizer in an amount ranging from 5 to 25% by weight, most preferably from 10 to 25% by weight, based on the total weight of the ink; (b) a carrier material in an amount ranging from 1 to 8% by weight, most preferably from 1 to 5% by weight, based on the total weight of the ink; and (c) a crystallization trigger substance in an amount ranging from 0.05 to 2.8% by weight, most preferably 0.1 to 2.5% by weight, based on the total weight of the ink; and (d) a buffer in an amount ranging from 64.2 to 93.95% by weight, most preferably from 67.5 to 98.9% by weight, based on the total weight of the ink; The composition comprises, and preferably consists of,
[0122] The biomimetic mineralizable 3D printing ink as defined herein is preferably produced by a method for its manufacture. The method for the manufacture of the biomimetic mineralizable 3D printing ink comprises: (a) providing a calcium cation-based compound which is a metastable calcium carbonate or a metastable calcium phosphate; (b) providing a carrier material; (c) providing a crystallization trigger substance; and (d) mixing the calcium cation-based compound, which is a metastable calcium carbonate or a metastable calcium phosphate of step (a), the carrier material of step (b), and the crystallization trigger substance of step (c); Includes.
[0123] With regard to the definitions of the biomimetic mineralizable 3D printing ink, calcium cation-based compound, carrier material, crystallization trigger substance, and preferred embodiments thereof, reference is made to the descriptions provided above when considering the technical details of the biomimetic mineralizable 3D printing ink of the present invention.
[0124] Step (d) is carried out by mixing the metastable calcium carbonate or metastable calcium phosphate calcium cation-based compound of step (a), the carrier material of step (b), and the crystallization trigger material of step (c). It is understood that any mixing (or stirring) means suitable for thoroughly mixing the components together may be used. Suitable devices for mixing, stirring, or agitation are known to those skilled in the art.
[0125] Step (d) may be carried out at room temperature, i.e. at a temperature of 20° C.±2° C., or at a temperature above the freezing point of the mixture prepared in step (d). For example, step (d) is carried out at a temperature of 10 to 50° C., preferably 15 to 45° C.
[0126] When the calcium cation based compound, which is a metastable calcium carbonate or a metastable calcium phosphate, further comprises a stabilizer, the method for producing a biomimetic mineralizable 3D printing ink comprises: (a) providing a calcium cation-based compound which is a metastable calcium carbonate or a metastable calcium phosphate, comprising a stabilizer; (b) providing a carrier material; (c) providing a crystallization trigger substance; and (d) mixing the calcium cation-based compound, which is a metastable calcium carbonate or a metastable calcium phosphate, with the stabilizer of step (a), the carrier material of step (b), and the crystallization trigger substance of step (c); Includes.
[0127] Biomineralized 3D printed articles and methods of manufacture According to a further aspect of the present invention, the biomimetic mineralizable 3D printing inks defined herein may be used to produce biomineralized 3D printed articles.
[0128] Thus, the present invention further relates to a method for producing a biomineralized 3D printed article, the method comprising the steps of: (a) providing a biomimetic mineralizable 3D printing ink; (b) printing the biomimetic mineralizable 3D printing ink into a predetermined shape using a 3D printer; and (c) curing the biomimetic mineralizable 3D printing ink at a temperature in the range of 10-50° C. to obtain a biomineralized 3D printed article; Includes.
[0129] With regard to the definition of the biomimetic mineralizable 3D printing ink and its preferred embodiments, reference is made to the descriptions provided above when considering the technical details of the biomimetic mineralizable 3D printing ink of the present invention.
[0130] Regarding method step (b), it should be noted that any 3D printer suitable for printing the article to be manufactured may be used in the present invention. For example, the 3D printer may be selected from pneumatic, extrusion and piston 3D printers. Such 3D printers are known to those skilled in the art and do not need to be described in further detail here.
[0131] In step (c) of the method for producing a biomineralized 3D printed article, the biomimetic mineralizable 3D printing ink is cured at a temperature in the range of 10-50° C. to obtain a biomineralized 3D printed article. For example, in step (c) the biomimetic mineralizable 3D printing ink is cured at a temperature in the range of 15-45° C. to obtain a biomineralized 3D printed article.
[0132] In one embodiment, the biomimetic mineralizable 3D printing ink is cured in step (c) at a temperature in the range of 15-40°C, most preferably in the range of 20-40°C.
[0133] Additionally or alternatively, the curing in step (c) is carried out for a curing time in the range of 2 hours to 21 days, preferably 12 hours to 19 days, and most preferably 24 hours to 18 days. For example, the curing in step (c) is carried out for a curing time in the range of 2 hours to 5 days, preferably 12 hours to 4 days, and most preferably 24 hours to 72 hours.
[0134] Additionally or alternatively, the curing in step (c) is carried out in an atmosphere of 3-6% by volume, preferably 4-6% by volume, most preferably 4.5-5.5% by volume of CO. 2 It is done by content.
[0135] Additionally or alternatively, the curing in step (c) is carried out at a humidity of greater than 75% by volume, preferably in the range of 80-100% by volume, and most preferably in the range of 85-99.5% by volume.
[0136] In one embodiment, the curing in step (c) thus comprises: (a) at a temperature in the range of 15 to 40°C, most preferably at a temperature in the range of 20 to 40°C, or (b) a curing time ranging from 2 hours to 21 days, preferably from 12 hours to 19 days, and most preferably from 24 hours to 18 days; or (c) CO in an atmosphere of 3 to 6% by volume, preferably 4 to 6% by volume, and most preferably 4.5 to 5.5% by volume. 2 By content, or (d) at a humidity of greater than 75% by volume, preferably in the range of 80 to 100% by volume, and most preferably in the range of 85 to 99.5% by volume; It will be held.
[0137] Preferably, the hardening in step (c) is carried out at high humidity, which leads to the crystallization of the calcium cation-based compound, which is a metastable calcium carbonate or a metastable calcium phosphate. Thus, the hardening in step (c) is carried out at high humidity, which leads to the crystallization of the calcium cation-based compound, which is a metastable calcium carbonate or a metastable calcium phosphate. (a) at a temperature in the range of 10 to 50° C., preferably 15 to 45° C., more preferably 15 to 40° C., and most preferably 20 to 40° C.; and (b) at a humidity of greater than 75% by volume, preferably in the range of 80 to 100% by volume, and most preferably in the range of 85 to 99.5% by volume; It is preferable that this be done.
[0138] In addition, the CO 2 The content is preferably kept within a certain range that favorably influences the formation of cells and the mineralization of the sample. Thus, the hardening in step (c) (a) at a temperature in the range of 10 to 50° C., preferably 15 to 45° C., more preferably 15 to 40° C., and most preferably 20 to 40° C.; and (b) at a humidity of greater than 75% by volume, preferably in the range of 80 to 100% by volume, and most preferably in the range of 85 to 99.5% by volume; and (c) CO in an atmosphere of 3 to 6% by volume, preferably 4 to 6% by volume, and most preferably 4.5 to 5.5% by volume. 2 The content is It is preferable that this be done.
[0139] It is understood that the curing is preferably carried out for a period of time ranging from 2 hours to 21 days, preferably from 12 hours to 19 days, and most preferably from 24 hours to 18 days. For example, the curing is carried out for a period of time ranging from 2 hours to 5 days, preferably from 12 hours to 4 days, and most preferably from 24 hours to 72 hours. Thus, the curing in step (c) is (a) at a temperature in the range of 10 to 50° C., preferably 15 to 45° C., more preferably 15 to 40° C., and most preferably 20 to 40° C.; and (b) at a humidity of greater than 75% by volume, preferably in the range of 80 to 100% by volume, and most preferably in the range of 85 to 99.5% by volume; and (c) CO in an atmosphere of 3 to 6% by volume, preferably 4 to 6% by volume, and most preferably 4.5 to 5.5% by volume. 2 In content, and (d) a curing time within the range of 2 hours to 21 days, preferably 12 hours to 19 days, most preferably 24 hours to 18 days, for example, 2 hours to 5 days, or 12 hours to 4 days, or 24 hours to 72 hours; It is preferable that this be done.
[0140] To subject the resulting biomineralized 3D printed article to final curing, the method preferably further comprises the step of drying the article, for example at elevated temperature or for a sufficient period of time.
[0141] Thus, the method for producing a biomineralized 3D printed article preferably comprises a further step (d) of drying the biomineralized 3D printed article obtained in step (c). In a preferred embodiment, the drying is carried out at a temperature of at least 50°C, more preferably at a temperature in the range of 60-100°C, most preferably at a temperature in the range of 65-90°C, or for a drying time in the range of 5h-36h, preferably at a temperature in the range of 5h-32h, most preferably at a drying time in the range of 6h-26h. For example, a drying time in the range of 5h-24h, preferably at a temperature in the range of 5h-18h, most preferably at a drying time in the range of 6h-12h. Preferably, the method for producing a biomineralized 3D printed article preferably further comprises a step (d) of drying the biomineralized 3D printed article obtained in step (c), preferably at a temperature of at least 50°C, more preferably at a temperature in the range of 60-100°C, most preferably at a temperature in the range of 65-90°C.
[0142] It will be appreciated that the final cure preferably further comprises drying the article at elevated temperature, which is carried out for a sufficient period of time, depending on the temperature applied.
[0143] In one embodiment, the drying is carried out so that the article has a low residual moisture content. However, from the viewpoint of the article to be manufactured, it is advantageous to avoid completely drying the article during drying in order to mimic nature and keep the cells alive. It is therefore preferred that as a result of the drying, the residual moisture content of the article, as measured by TGA, is in the range of 1-8 wt.%, preferably 2-5 wt.%.
[0144] The method therefore comprises a further step (d) of drying the biomineralized 3D printed article obtained in step (c), preferably at a temperature of at least 50° C., more preferably at a temperature in the range of 60-100° C., most preferably at a temperature in the range of 65-90° C., and for a drying time in the range of 5 h to 36 h, preferably 5 h to 32 h, most preferably 6 h to 26 h, e.g. for a drying time in the range of 5 h to 24 h, preferably 5 h to 18 h, most preferably 6 h to 12 h.
[0145] In this respect, the method for producing a biomineralized 3D printed article preferably comprises: (a) providing a biomimetic mineralizable 3D printing ink; (b) printing the biomimetic mineralizable 3D printing ink into a predetermined shape using a 3D printer; (c) curing the biomimetic mineralizable 3D printing ink at a temperature in the range of 10-50° C. to obtain a biomineralized 3D printed article; and (d) drying the biomineralized 3D printed article obtained in step (c) at a temperature of preferably at least 50°C, more preferably in the range of 60-100°C, most preferably in the range of 65-90°C, and for a drying time in the range of 5 hours to 36 hours, preferably in the range of 5 hours to 32 hours, most preferably in the range of 6 hours to 26 hours; Includes.
[0146] According to a further aspect, the present invention also relates to a biomineralized 3D printed article, which is preferably obtainable by the method for producing a biomineralized 3D printed article as defined herein.
[0147] Therefore, biomineralized 3D printed articles can: (a) providing a biomimetic mineralizable 3D printing ink; (b) printing the biomimetic mineralizable 3D printing ink into a predetermined shape using a 3D printer; and (c) curing the biomimetic mineralizable 3D printing ink at a temperature in the range of 10-50° C. to obtain a biomineralized 3D printed article; The method can be obtained by a method for producing a biomineralized 3D printed article comprising the steps of:
[0148] Preferably, the biomineralized 3D printed article comprises: (a) providing a biomimetic mineralizable 3D printing ink; (b) printing the biomimetic mineralizable 3D printing ink into a predetermined shape using a 3D printer; and (c) curing the biomimetic mineralizable 3D printing ink at a temperature in the range of 10-50° C. to obtain a biomineralized 3D printed article; and (d) drying the biomineralized 3D printed article obtained in step (c) at a temperature of preferably at least 50°C, more preferably in the range of 60-100°C, most preferably in the range of 65-90°C, and for a drying time in the range of 5 hours to 36 hours, preferably in the range of 5 hours to 32 hours, most preferably in the range of 6 hours to 26 hours; The method can be obtained by a method for producing a biomineralized 3D printed article comprising the steps of:
[0149] It is understood that the article is preferably a dental reconstruction material, a ceramic substitute, a mollusc shell substitute, a nacre substitute, a dentin substitute, a tooth substitute, or a bone substitute.
[0150] In view of the advantageous effects obtained in the present invention, another aspect of the present application further relates to the use of a biomimetic mineralizable 3D printing ink for 3D printing.
[0151] With regard to the definition of the biomimetic mineralizable 3D printing ink and its preferred embodiments, reference is made to the descriptions provided above when considering the technical details of the biomimetic mineralizable 3D printing ink of the present invention.
[0152] The inventors have found that the crystallization trigger material is advantageous in increasing the hardness of the construct after 3D printing. Therefore, a further aspect of the present invention relates to the use of a crystallization trigger material, which is an oligopeptide selected from the group including the HABP family of oligopeptides and the P11 family of oligopeptides, for 3D printing.
[0153] Alternatively or additionally, there is provided the use of a calcium cation based compound that is a metastable calcium carbonate or a metastable calcium phosphate for 3D printing.
[0154] The following examples and tests are illustrative of the invention but are not intended to limit it in any way. [Brief description of the drawings]
[0155] [Figure 1] FIG. 1 shows SEM images of the fabricated ACP (left) and the ACP after printing (right). [Diagram 2] FIG. 2 shows an SEM photograph of the produced ACC. [Diagram 3] FIG. 3 shows a comparison of the hardness of the produced ACP inks. [Figure 4] FIG. 4 shows the Vickers hardness of Example 2. [Diagram 5] FIG. 5 shows the Vickers hardness of Example 3. [Figure 6] FIG. 6 shows the Vickers hardness of Example 4. [Figure 7] FIG. 7 shows a comparison of the hardness of the produced ACC inks. [Figure 8] FIG. 8 shows the XRD comparison of the ACP before and after 3D printing of Example 4. [Figure 9] FIG. 9 shows a comparison of FTIR of ACP before and after 3D printing in Example 4. Example 1
[0156] Materials used CaCl 2 2H2 O ≧99% Sigma Aldrich Na 2 CO 3 ≧99.5% Sigma Aldrich LO-phosphoserine ≧98% TCI Ca(NO 3 ) 2 4H 2 O ≧99% Sigma Aldrich (NH 4 ) 2 HPO 4 ≧98% Sigma Aldrich NH 4 OH solution (28.0~30.0% NH 3 Reference) Sigma Aldrich Whatman cellulose nitrate membrane filter, Φ9cm, 0.8μm Fann filter, special hard filter paper, Φ9cm, 2~5μm Amorphous calcium phosphate (ACP) and amorphous calcium carbonate (ACC) manufactured by Omya AG Methylcellulose (MC) from Sigma Aldrich NaOH from Sigma Aldrich Na 2 HPO 4 Made by Sigma Aldrich Citric Acid Sigma Aldrich 1×PBS (pH=7.4) from Sigma Aldrich Peptide P11-4 (sequence: CH3CO-QQRFEWEFEQQ-NH2) from Credentis AG
[0157] Manufacturing of ACP and ACC Preparation of ACP: Precipitation of calcium phosphate salts in aqueous solution was carried out by adding calcium nitrate tetrahydrate aqueous solution in one step while stirring diammonium phosphate aqueous solution. Precipitation was observed during this process. ACP was recovered by filtration and washing steps followed by freeze-drying.
[0158] Details of the solution preparation and synthesis are given in Tables 1 and 2 below. [Table 1] [Table 2]
[0159] The final product was stored in a desiccator until further use.
[0160] FIG. 1 shows SEM images of the fabricated ACP (left) and the ACP after printing (right).
[0161] Preparation of ACC: Precipitation of calcium carbonate salt in aqueous solution was carried out by adding aqueous calcium chloride solution in one step while stirring aqueous sodium carbonate solution. Precipitation was observed during this process. ACC was recovered by filtration and washing steps followed by freeze-drying.
[0162] Details of the solution preparation and synthesis are given in Tables 3 and 4 below. [Table 3] [Table 4]
[0163] The final product was stored in a desiccator until further use.
[0164] FIG. 2 shows an SEM photograph of the produced ACC.
[0165] Preparation of solutions Stock solution MC 15cp (methylcellulose) light (7.4% w / w) 8 g of MC is dissolved in 100 g of PBS (phosphate buffered saline) and allowed to swell overnight at 4°C. P11-4 peptide (1% w / w, 3% w / w) (for 3 ml) - adjust according to ml Peptide P11-4 was dissolved in 0.04M Na 2 HPO 4 , 1 M NaOH, and 0.02 M citric acid solution.
[0166] Characterization method TGA Thermogravimetric analysis was performed on a Perkin Elmer TGA 4000. The TGA program was: 30.00° C., hold for 1.0 min, and ramp from 30.00° C. to 900.00° C. at 10.00° C. / min.
[0167] BET The specific surface area of the powders was measured with a Micromeritics ASAP 2460. Degassing of the samples was carried out under vacuum. The samples were measured according to the ISO 9277 standard.
[0168] Particle size distribution Particle size distribution was performed by dynamic light scattering using a Malvern Zetasizer Nano ZS. For sample preparation, a dispersion containing 0.1 wt% particles and 0.0021 wt% polyacrylate dispersant in an aqueous solution was prepared. The suspension was high shear mixed for 3 minutes, followed by sonication for 30 minutes. The samples were measured.
[0169] Vickers experiment Measurements were performed using a Struers DURAMIN-40 M1 (https: / / www.struers.com / en / Products / Hardness-testing / Hardness-testing-equipment / Duramin-40).
[0170] To obtain a flat surface for indentation, the samples were manually ground (1000 grade paper), polished (cotton cloth), and cleaned with lint-free paper towels. After analysis, the surfaces were rinsed with N 2The tip was flushed with water. The location of the indentation was selected by optical inspection and navigation with a micrometer stage. A load appropriate for HV0.01 was then applied. The tip was held at the force position for 10 seconds and then removed. The size of the indentation was measured optically, followed by an automated evaluation of the Vickers hardness.
[0171] The measuring equipment operates according to the standards ASTM E384, ISO 6507, and JIS Z 2244.
[0172] XRD Approximately 0.16cm 3 The samples were mounted on a PMMA sample holder providing a flat circular (d=20 mm) surface for XRD analysis. The samples were then analyzed according to Bragg's law using a Bruker D8 Advance ECO powder diffractometer equipped with a 1 kW X-ray tube operated at 40 kV and 25 mA, a θ-θ (Bragg-Brentano) goniometer, and a LYNXEYE XE-T detector, scanning from 3° to 70° 2θ in steps of 0.02° 2θ, with 0.5 seconds per step. In all experiments, nickel-filtered CuK α Radiation (λ=1.54060 10 -10 A 300 Hz diffraction (300 Hz) was used. Samples were rotated at 15 rpm during the measurements to maximize random distribution of the analyzed crystal faces. The obtained powder diffraction patterns were compared with reference patterns from the ICDD PDF library and qualitatively interpreted with respect to inorganic content using the Bruker DIFFRACsuite software package EVA.
[0173] FTIR (Perkin-Elmer) FTIR spectrum of the sample in attenuated total reflectance (ATR) for species confirmation. FTIR spectra were collected using a single reflection ATR unit (Gladi®-ATR). Spectral data were slightly smoothed (value 20), baseline corrected, and normalized to 1.5A (absorbance equivalent to 3.16% transmittance).
[0174] Field Emission Scanning Electron Microscope (FESEM) The examination was carried out using a field emission scanning electron microscope (Zeiss Sigma VP) with two different detectors. 1. The image from the secondary electron detector (SE) shows the grain shape of the sample. 2. Fine structures were revealed using an in-lens secondary electron detector (InLens).
[0175] example Prior to producing the ink, the gel liquid materials MC and peptides were prepared as follows. 1. 8 g of MC was dissolved in 100 g of PBS (phosphate buffered saline) and allowed to swell overnight at 4°C. 2. 90.63 mg of peptide P11-4 was dissolved in 100.6 μl of 1 M NaOH / 1.365 ml of 0.04 Na 2 HPO 4 As a final step in the self-assembly, 1.5 ml of 0.02 M citric acid was added.
[0176] For the preparation of the ACP ink, the gel liquid materials (MC and P11-4) were mixed first, followed by the addition of the inorganic portion (ACP) and then mixing all the materials.
[0177] 3D printed article samples were produced by direct extrusion through a metal syringe needle (0.3 mm inner diameter) or a conical PLA needle (0.4 mm inner diameter) using a 3D printer RegenHU 3Discovery. The ink was filled into a 3 ml plastic syringe and a tip was attached. Air pressure was applied to extrude the ink until a flow rate of 1-2 mm / s was measured. 3D printed article samples were then printed line by line and layer by layer (3 mm height for each layer, total of 3 layers) in a 1 x 1 cm square geometry by computer-controlled motorized 3D stage movement.
[0178] The 3D printed article samples were then stored at 37°C, 99% humidity by volume, and 5% CO by volume for curing. 2The cells were stored in an incubator at 0.04, 0.17, 1, 2, 6, 9, and 16 days for defined time intervals.
[0179] The 3D printed article samples were further dried at 70° C. for 24 hours and stored in a desiccator for further characterization by Vickers, XRD, and FTIR.
[0180] The 3D printed article samples produced are shown in Table 5 below. [Table 5]
[0181] For the preparation of the ACC ink, the gel liquid materials (MC and P11-4) were mixed first, followed by the addition of the inorganic portion (ACC) and then mixing all the materials.
[0182] 3D printed article samples were produced by direct extrusion through a metal syringe needle (0.3 mm inner diameter) or a conical PLA needle (0.4 mm inner diameter) using a 3D printer RegenHU 3Discovery. The ink was filled into a 3 ml plastic syringe and a tip was attached. Air pressure was applied to extrude the ink until a flow rate of 1-2 mm / s was measured. 3D printed article samples were then printed line by line and layer by layer (3 mm height for each layer, total of 3 layers) in a 1 x 1 cm square geometry by computer-controlled motorized 3D stage movement.
[0183] The 3D printed article samples were then stored at 37°C, 99% humidity by volume, and 5% CO by volume for curing. 2 The cells were stored in an incubator at 4 °C for 16 days.
[0184] The 3D printed article samples were further dried at 70° C. for 24 hours and stored in a desiccator for further characterization by Vickers, XRD, and FTIR.
[0185] The 3D printed article samples produced are shown in Table 6 below. [Table 6]
[0186] The use of crystallization trigger substances such as peptides is advantageous in increasing the hardness of the construct after 3D printing. This was supported by the hardness measurements and comparison of the formulations containing higher concentrations of crystallization trigger substances, as seen in Figures 3, 4, 5, and 6 (Examples 2, 3, 4, and 6). These samples show even higher hardness than the control (tooth). Time also plays a role in the increase in hardness, which can be seen in the formulations with higher crystallization trigger substance content (Examples 3 and 4). This again suggests that the crystallization trigger substance is strongly involved in the hardening of the construct. It was also evident that the amorphous phase was transformed into a crystalline phase, as shown by XRD and FTIR (Figures 8 and 9). In particular, the broadening of the peaks shown for ACP in Figure 8 makes it clear that there is a metastable calcium phosphate, especially an amorphous calcium phosphate, with a crystallinity of less than 20 wt% based on the total weight of the calcium phosphate.
Claims
1. (a) a calcium cation-based compound which is a metastable calcium carbonate or a metastable calcium phosphate; (b) a carrier material, and (c) a crystallization trigger substance; 1. A biomimetic mineralizable 3D printing ink comprising:
2. 2. The biomimetic mineralizable 3D printing ink of claim 1, wherein the calcium cation based compound has a crystallinity of less than 50 wt%, preferably less than 40 wt%, more preferably less than 30 wt%, and most preferably less than 20 wt%, based on the total weight of the calcium cation based compound.
3. The calcium cation-based compound has a weight median particle size d in the range of 1 to 500 nm, preferably 50 to 400 nm, and most preferably 100 to 350 nm, as determined by dynamic light scattering. 50 3. A biomimetic mineralizable 3D printing ink according to claim 1 or 2, comprising:
4. 4. A biomimetic mineralizable 3D printing ink according to any one of claims 1 to 3, wherein the carrier material is a material suitable for forming a hydrogel, preferably selected from the group comprising gelatin, methylcellulose, alginate, agarose, fibrin, hyaluronic acid, proteins such as gelatin, nidogen, collagen, and heparan sulfate proteoglycans, and mixtures thereof, K-carrageenan, poly(ethylene glycol) (PEG), polycaprolactone (PCL), poloxamer, peptides, and mixtures thereof.
5. 5. A biomimetic mineralizable 3D printing ink according to any one of claims 1 to 4, wherein the crystallization trigger substance is a peptide, oligopeptide or protein, preferably the crystallization trigger substance is an oligopeptide, more preferably the crystallization trigger substance is an oligopeptide comprising 11 amino acid residues and comprising a hydrophobic aromatic core.
6. The crystallization trigger substance is an oligopeptide of the HABP family, preferably HABP1 and HABP2, and an oligopeptide of the P11 family, preferably P11-4, P11-8, P11-9, P11-12, P11-13, P11-14, P11-15, P11-16, P11-17, P11-18, P11-19, P11-20, P11-24, P11-25, P11-26, P11-2 6. A biomimetic mineralizable 3D printing ink according to any one of claims 1 to 5, wherein the oligopeptide is selected from the group consisting of P11-family oligopeptides P11-7, P11-28, P11-29, P11-30, P11-31, P11-32 and mixtures, most preferably P11-4, optionally in association with a negatively charged or a positively charged polysaccharide.
7. 7. A biomimetic mineralizable 3D printing ink according to any one of claims 1 to 6, wherein the crystallization trigger substance is an oligopeptide in which the amino acids at positions 4 and 8 are phenylalanine (F) and the amino acid at position 6 is tryptophan (W), and / or both amino acid residues at positions 5 and 7 of the peptide are ornithine (O) or glutamic acid (E).
8. The ink is (a) the calcium cation-based compound in an amount ranging from 2 to 30% by weight, preferably from 5 to 25% by weight, and most preferably from 10 to 25% by weight, based on the total weight of the ink; and (b) the carrier material in an amount ranging from 1 to 10% by weight, preferably from 1 to 8% by weight, and most preferably from 1 to 5% by weight, based on the total weight of the ink; and (c) the crystallization trigger material in an amount ranging from 0.05 to 3 wt. %, preferably 0.05 to 2.8 wt. %, and most preferably 0.1 to 2.5 wt. %, based on the total weight of the ink; and (d) a buffer in an amount ranging from 57 to 96.95% by weight, preferably from 64.2 to 93.95% by weight, and most preferably from 67.5 to 98.9% by weight, based on the total weight of the ink; A biomimetic mineralizable 3D printing ink according to any one of claims 1 to 7, comprising
9. A biomimetic mineralizable 3D printing ink according to any one of claims 1 to 8, wherein the calcium cation based compound which is a metastable calcium carbonate or a metastable calcium phosphate comprises a stabiliser.
10. 10. The biomimetic mineralizable 3D printing ink of claim 9, wherein the stabilizing agent is selected from the group comprising magnesium chloride, polyaspartic acid, glutamic acid, polyacrylic acid, phosphates such as L-O-phosphoserine, sodium dihydrogen phosphate, and disodium hydrogen phosphate, sugars, EDTMP, xanthan, polysorbates, citric acid, ethylenediamine, extracts from biological samples, dual hydrophilic block copolymers, and mixtures thereof.
11. (a) providing a calcium cation-based compound which is a metastable calcium carbonate or a metastable calcium phosphate; (b) providing a carrier material; (c) providing a crystallization trigger substance; and (d) mixing the calcium cation-based compound, which is a metastable calcium carbonate or a metastable calcium phosphate of step (a), the carrier material of step (b), and the crystallization trigger substance of step (c); A method for producing a biomimetic mineralizable 3D printing ink according to any one of claims 1 to 10, comprising:
12. A method for producing a biomineralized 3D printed article, comprising the steps of: (a) providing a biomimetic mineralizable 3D printing ink according to any one of claims 1 to 10, (b) printing the biomimetic mineralizable 3D printing ink into a predetermined shape using a 3D printer; and (c) curing said biomimetic mineralizable 3D printing ink at a temperature in the range of 10-50°C, preferably 15-45°C, to obtain said biomineralized 3D printed article.
13. The curing in step (c) (a) at a temperature in the range of 15 to 40° C., most preferably at a temperature in the range of 20 to 40° C.; and / or (b) a curing time ranging from 2 hours to 21 days, preferably from 12 hours to 19 days, and most preferably from 24 hours to 18 days; and / or (c) CO in an atmosphere of 3-6% by volume, preferably 4-6% by volume, and most preferably 4.5-5.5% by volume. 2 In content, and / or (d) at a humidity of greater than 75% by volume, preferably in the range of 80 to 100% by volume, and most preferably in the range of 85 to 99.5% by volume; The method of claim 12, wherein
14. 14. The method according to claim 12 or 13, wherein the method further comprises a step (d) of drying the biomineralized 3D printed article obtained in step (c), preferably at a temperature of at least 50°C, more preferably at a temperature in the range of 60-100°C, most preferably 65-90°C, and / or for a drying time in the range of 5 hours to 36 hours, preferably 5 hours to 32 hours, most preferably 6 hours to 26 hours.
15. A biomineralized 3D printed article obtainable by the method according to any one of claims 12 to 14.
16. 16. The biomineralized 3D printed article of claim 15, wherein the article is a dental reconstruction material, a ceramic substitute, a mollusk shell substitute, a nacre substitute, a dentin substitute, a tooth substitute, or a bone substitute.
17. The use of a crystallization trigger substance, which is an oligopeptide selected from the group including HABP family of oligopeptides and P11 family of oligopeptides, for 3D printing.
